Ojjaara and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with Ojjaara (momelotinib).
Caffeine Momelotinib
Moderate Drug Interaction
Consumer information for this interaction is not currently available.
MONITOR: Coadministration of momelotinib may decrease the plasma concentrations and effects of drugs that are substrates of CYP450 1A2. The proposed mechanism, based on in vitro data, is increased drug clearance due to momelotinib-mediated induction of the CYP450 1A2 isoenzyme. However, clinical data are not available.
MANAGEMENT: Caution is recommended with the concomitant use of momelotinib and CYP450 1A2 substrates, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever momelotinib is added to or withdrawn from therapy with these drugs. Individual product labeling for the coadministered drug may also be consulted for specific guidance.
Nicotine Momelotinib
Moderate Drug Interaction
Consumer information for this interaction is not currently available.
MONITOR: Coadministration of momelotinib may increase the plasma concentrations and effects of drugs that are substrates of CYP450 2B6. The proposed mechanism, based on in vitro data, is decreased drug clearance due to momelotinib-mediated inhibition of the CYP450 2B6 isoenzyme. However, clinical data are not available.
MANAGEMENT: Caution is advised if the momelotinib is administered with sensitive substrates of CYP450 2B6. Patients should be monitored for the development of adverse effects. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever momelotinib is added to or withdrawn from therapy with these drugs. Individual product labeling for the coadministered drug may also be consulted for specific guidance.
Switch to professional interaction data
Ojjaara drug interactions
There are 409 drug interactions with Ojjaara (momelotinib).
Ojjaara disease interactions
There are 5 disease interactions with Ojjaara (momelotinib) which include:
Report options
More about Ojjaara (momelotinib)
- Ojjaara consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Vonjo
Vonjo (pacritinib) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Inrebic
Inrebic is used to treat certain types of myelofibrosis (MF) in adults. It is an oral capsule taken ...
Fedratinib
Fedratinib is used for certain types of myelofibrosis (MF) in adults, relieving night sweats ...
Pacritinib
Pacritinib (brand name Vonjo) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Ruxolitinib
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV) ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
